The publication shows the utility of OGM in solid tumor research with a study on the discovery of complex genome rearrangements in prostate cancer

Bionano Genomics

Bionano Genomics

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study that uses optical genome mapping (OGM) to discover structural variants (SVs) and balanced rearrangements relevant to the pathogenesis of prostate cancer. OGM identified SVs in all samples, potentially improving the success rate of finding disease-causing variants and simplifying the detection process.

In the study published in Cancer Cell InternationalIn this study, the authors analyzed ten consecutive PCa samples to investigate the ability of OGM to detect genetic aberrations and complex SVs that may be associated with aggressive disease course and resistance to androgen receptor-targeted therapies in solid tumor cancers. The PCa genome is characterized by frequent balanced rearrangements that affect many oncogenes and tumor suppressor genes. The study reported that OGM helped identify alterations, deletions, and translocations that may cause or contribute to genomic instability in cancer cells. The study authors highlight the challenges associated with the use of conventional methods and cite OGM’s robust detection of encoded rearrangements at high resolution as evidence of its potential application as a first-line method in solid tumor analysis.

“We have seen tremendous progress in the application of OGM in structural genetic disorders. Within oncology research, many previous publications have focused on analysis of blood or bone marrow. This paper serves as a good demonstration of the utility of OGM for solid tumor research. The study authors show that OGM can be more sensitive to detecting large structural differences and balanced rearrangements than conventional methods or whole-genome sequencing. We believe this study provides a great example of how OGM can assist in a sequencing-based approach to the molecular assessment of solid tumours,” commented Eric Holmelin, PhD, President and CEO of Bionano Genomics.

This post can be found over here.

About the Bionano Genome

Bionano Genomics is a company that provides genomic analysis solutions that can enable researchers and clinicians to uncover answers to challenging questions in biology and medicine. The company’s mission is to change the way the world sees the genome through OGM solutions, diagnostic services, and software. The company provides OGM solutions for applications across basic, translational and clinical research. Through Lineagen, Inc. d / b / a Bionano Laboratories, the Company also provides diagnostic tests for patients with clinical presentations compatible with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading platform-less software solution that integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation, and reporting of copy number variants, single-nucleotide variants, and absences of heterozygosity across the genome into a single view. unified. For more information visit www.bionanogenomics.comAnd the www.bionanolaboratories.com or www.biodiscovery.com

Forward-looking statements for Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “could,” “may,” “potential” and similar expressions (as well as other words or expressions that refer to events or future conditions or circumstances) convey uncertainty of future events or results and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our current intentions, beliefs, expectations, projections, analyses, or expectations regarding, among other things, the ability and usefulness of OGM to detect SVs and balanced rearrangements related to PCa pathogenesis; the ability and usefulness of OGM to detect cryptic rearrangements when compared to conventional methods; The ability and usefulness of OGM to complement and aid sequencing-based molecular assessment of solid tumor. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments could differ materially from those projected or implied by these forward-looking statements. Factors that could cause such a divergence include risks and uncertainties associated with: global and macroeconomic events, such as the impact of the COVID-19 pandemic and the ongoing Ukraine-Russia conflict and related sanctions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; OGM fails to achieve useful integration and aid in sequencing-based molecular assessment of solid tumor; OGM failed to detect SVs and balanced rearrangements relevant to PCa pathogenesis; OGM failed to detect cryptic rearrangements when compared to conventional methods; The results of the prospective study are inconsistent with the findings reported in the referenced publication above; changes to our strategic and business plans; our ability to obtain sufficient financing to fund our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and overall financial condition, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings which we subsequently filed with the Securities and Exchange Commission. All forward-looking statements in this press release speak only as of the date they are made and are based on management’s assumptions and estimates as of the date. We undertake no obligation to publicly update any forward-looking statements, whether as a result of receipt of new information, future events or otherwise.

Contacts
Company contact:
Eric Holmelin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com

Leave a Comment